The North American market for active pharmaceutical ingredients shelters the presence of highly established and regulated pharmaceutical industry, a factor that has been primarily responsible for the region for capturing the largest market share in 2018 in the global API market. As per the market analysis by Inkwood Research, the regional market is expected to escalate at a CAGR of 5.05% during the forecasting years of 2019-2027.

NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FORECAST 2019-2027

North America Active Pharmaceutical Ingredients Market by Types (Generic Apis, Innovative Apis) by Manufacturers (Captive Apis, Merchant Apis) by Synthesis (Biotech, Synthetic) by Application (Cardiovascular Disease, Oncology, Cns and Neurological Disorders, Orthopedic Disorders, Endocrinology, Pulmonology, Gastrointestinal Disorders, Nephrology, Ophthalmology, Other Application) by Geography.

Request free sample

The pharmaceutical drugs are available in the form of tablets or capsules, and they are a non-homogenous mixture of various active chemical(s) contained in the drugs termed as ‘active pharmaceutical ingredients’ or API in short and an excipient part, known as a carrier. Although, it is the quantity of the API that is considered while prescribing a drug.

The North American market for active pharmaceutical ingredients shelters the presence of a highly established and regulated pharmaceutical industry, a factor that has been primarily responsible for the region for capturing the largest market share in 2018 in the global API market. As per the market analysis by Inkwood Research, the regional market is expected to escalate at a CAGR of 5.05% during the forecasting years of 2019-2027.

The intensive technological development coupled with high economic growth in the North American region is chiefly driving the market growth. Additionally, the increasing prevalence of cancer and other lifestyle-induced diseases is responsible for tremendous growth in R&D activities for drugs. Furthermore, the majority of the pharmaceutical players are based on this region.

The United States and Canada are considered for the market study of the region. The US market is expected to hold the largest market share by the end of 2027, mainly because of the rising prevalence of lifestyle-inducing diseases such as diabetes and cardiovascular disorders, which is further increasing the demand for more effective drugs.

Sun Pharmaceuticals Industries, Ltd., Bristol-Myers Squibb, Merck & Co., Inc., Albemarle Corporation, Teva Pharmaceutical Industries, Ltd., Lonza Group AG, Mylan N.V., Novartis, Bayer AG, Aurobindo Pharma, Eli Lilly and Company, AbbVie, Inc., Dr. Reddy’s Laboratories, Cipla, and Boehringer Ingelheim GmbH are the major companies that are operating in the region that have been comprehensively profiled in the report.

 

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

    1. RESEARCH SCOPE
      • STUDY GOALS
      • SCOPE OF THE MARKET STUDY
      • WHO WILL FIND THIS REPORT USEFUL?
      • STUDY AND FORECASTING YEARS
    2. RESEARCH METHODOLOGY
      • SOURCES OF DATA
        • SECONDARY DATA
        • PRIMARY DATA
      • TOP-DOWN APPROACH
      • BOTTOM-UP APPROACH
      • DATA TRIANGULATION
    3. EXECUTIVE SUMMARY
      • MARKET SUMMARY
      • KEY FINDINGS
        • INNOVATIVE APIS HOLDS THE LARGEST MARKET SHARE IN TERMS OF ACTIVE PHARMACEUTICAL INGREDIENTS TYPE
        • MERCHANT APIS ARE THE FASTEST GROWING MANUFACTURERS
        • BIOTECH IS THE FASTEST GROWING SYNTHESIS SEGMENT
        • ONCOLOGY IS THE MAJORLY USED APPLICATION
    1. MARKET DYNAMICS
      • MARKET SCOPE & DEFINITION
      • MARKET DRIVERS
        • GROWING GERIATRIC POPULATION
        • GROWING PREVALENCE OF INFECTIOUS DISEASES AND HOSPITAL ACQUIRED INFECTIONS
        • INCREASING INCIDENCE OF AGE-RELATED DISEASES
      • MARKET RESTRAINTS
        • HIGH COST OF INVESTMENT AND PRODUCTION COST
        • AGGRESSIVE COMPETITION AMONG API MANUFACTURERS
      • MARKET OPPORTUNITIES
        • GAINING POPULARITY FOR TARGETED THERAPY
        • GROWING PREFERENCE FOR OUTSOURCING APIS
        • IMPLEMENTING MEASURES AGAINST COUNTERFEIT DRUGS
      • MARKET CHALLENGES
        • STRINGENT GOVERNMENT REGULATIONS
        • AVAILABILITY OF COUNTERFEIT PRODUCTS
    1. MARKET BY TYPES
      • GENERIC APIS
      • INNOVATIVE APIS
    2. MARKET BY MANUFACTURERS
      • CAPTIVE APIS
      • MERCHANT APIS
    3. MARKET BY SYNTHESIS
      • BIOTECH
        • MONOCLONAL ANTIBODIES
        • RECOMBINANT PROTEINS
        • VACCINES
      • SYNTHETIC
    4. MARKET BY APPLICATION
      • CARDIOVASCULAR DISEASE
      • ONCOLOGY
      • CNS AND NEUROLOGICAL DISORDERS
      • ORTHOPEDIC DISORDERS
      • ENDOCRINOLOGY
      • PULMONOLOGY
      • GASTROINTESTINAL DISORDERS
      • NEPHROLOGY
      • OPHTHALMOLOGY
      • OTHER APPLICATION
    5. KEY ANALYTICS
      • PORTER’S FIVE FORCES MODEL
        • THREAT OF NEW ENTRANTS
        • THREAT OF SUBSTITUTE
        • BARGAINING POWER OF BUYERS
        • BARGAINING POWER OF SUPPLIERS
        • THREAT OF COMPETITIVE RIVALRY
      • PESTEL ANALYSIS
      • SUPPLY CHAIN ANALYSIS
      • OPPORTUNITY MATRIX
    6. GEOGRAPHICAL ANALYSIS
      • NORTH AMERICA
        • THE UNITED STATES
        • CANADA
    1. COMPETITIVE LANDSCAPE
      • MARKET POSITION ANALYSIS
      • COMPANY PROFILES
        • ABBVIE, INC.
        • ALBEMARLE CORPORATION
        • AUROBINDO PHARMA
        • BAYER AG
        • BOEHRINGER INGELHEIM GMBH
        • BRISTOL-MYERS SQUIBB
        • CIPLA
        • REDDY’S LABORATORIES
        • ELI LILLY AND COMPANY
        • LONZA GROUP AG
        • MERCK & CO., INC.
        • MYLAN N.V.
        • NOVARTIS
        • SUN PHARMACEUTICALS INDUSTRIES, LTD.
        • TEVA PHARMACEUTICAL INDUSTRIES LTD.

    TABLE LIST

    TABLE 1        NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)

    TABLE 2        NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY TYPES 2019-2027 ($ MILLION)

    TABLE 3        NORTH AMERICA GENERIC APIS MARKET 2019-2027 ($ MILLION)

    TABLE 4        NORTH AMERICA INNOVATIVE APIS MARKET 2019-2027 ($ MILLION)

    TABLE 5        NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MANUFACTURERS 2019-2027 ($ MILLION)

    TABLE 6        NORTH AMERICA CAPTIVE APIS MARKET 2019-2027 ($ MILLION)

    TABLE 7        NORTH AMERICA MERCHANT APIS MARKET 2019-2027 ($ MILLION)

    TABLE 8        NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY SYNTHESIS 2019-2027 ($ MILLION)

    TABLE 9        NORTH AMERICA BIOTECH MARKET 2019-2027 ($ MILLION)

    TABLE 10      NORTH AMERICA BIOTECH MARKET BY TYPES 2019-2027 ($ MILLION)

    TABLE 11      NORTH AMERICA MONOCLONAL ANTIBODIES MARKET 2019-2027 ($ MILLION)

    TABLE 12      NORTH AMERICA RECOMBINANT PROTEINS MARKET 2019-2027 ($ MILLION)

    TABLE 13      NORTH AMERICA VACCINES MARKET 2019-2027 ($ MILLION)

    TABLE 14      NORTH AMERICA SYNTHETIC MARKET 2019-2027 ($ MILLION)

    TABLE 15      NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY APPLICATION 2019-2027 ($ MILLION)

    TABLE 16      NORTH AMERICA CARDIOVASCULAR DISEASE MARKET 2019-2027 ($ MILLION)

    TABLE 17      NORTH AMERICA ONCOLOGY MARKET 2019-2027 ($ MILLION)

    TABLE 18      NORTH AMERICA CNS AND NEUROLOGICAL DISORDERS MARKET 2019-2027 ($ MILLION)

    TABLE 19      NORTH AMERICA ORTHOPEDIC DISORDERS MARKET 2019-2027 ($ MILLION)

    TABLE 20      NORTH AMERICA ENDOCRINOLOGY MARKET 2019-2027 ($ MILLION)

    TABLE 21      NORTH AMERICA PULMONOLOGY MARKET 2019-2027 ($ MILLION)

    TABLE 22      NORTH AMERICA GASTROINTESTINAL DISORDERS MARKET 2019-2027 ($ MILLION)

    TABLE 23      NORTH AMERICA NEPHROLOGY MARKET 2019-2027 ($ MILLION)

    TABLE 24      NORTH AMERICA OPHTHALMOLOGY MARKET 2019-2027 ($ MILLION)

    TABLE 25      NORTH AMERICA OTHER APPLICATION MARKET 2019-2027 ($ MILLION)

    TABLE 26      NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY COUNTRY 2019-2027 ($ MILLION)

    TABLE 27      ACTIVE PHARMACEUTICAL INGREDIENTS COMPANY MARKET POSITION ANALYSIS 2017

    FIGURE LIST

    FIGURE 1      NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)

    FIGURE 2      NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE BY TYPES 2018 & 2027 (%)

    FIGURE 3      NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GENERIC APIS 2019-2027 ($ MILLION)

    FIGURE 4      NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY INNOVATIVE APIS 2019-2027 ($ MILLION)

    FIGURE 5      NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE BY MANUFACTURERS 2018 & 2027 (%)

    FIGURE 6      NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY CAPTIVE APIS 2019-2027 ($ MILLION)

    FIGURE 7      NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY MERCHANT APIS 2019-2027 ($ MILLION)

    FIGURE 8      NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE BY SYNTHESIS 2017 & 2027 (%)

    FIGURE 9      NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY BIOTECH 2019-2027 ($ MILLION)

    FIGURE 10   NORTH AMERICA BIOTECH MARKET BY MONOCLONAL ANTIBODIES 2019-2027 ($ MILLION)

    FIGURE 11   NORTH AMERICA BIOTECH MARKET BY RECOMBINANT PROTEINS 2019-2027 ($ MILLION)

    FIGURE 12   NORTH AMERICA BIOTECH MARKET BY VACCINES 2019-2027 ($ MILLION)

    FIGURE 13   NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY SYNTHETIC 2019-2027 ($ MILLION)

    FIGURE 14   NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE BY APPLICATION 2018 & 2027 (%)

    FIGURE 15   NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY CARDIOVASCULAR DISEASE 2019-2027 ($ MILLION)

    FIGURE 16   NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY ONCOLOGY 2019-2027 ($ MILLION)

    FIGURE 17   NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY CNS AND NEUROLOGICAL DISORDERS 2019-2027 ($ MILLION)

    FIGURE 18   NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY ORTHOPEDIC DISORDERS 2019-2027 ($ MILLION)

    FIGURE 19   NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY ENDOCRINOLOGY 2019-2027 ($ MILLION)

    FIGURE 20   NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY PULMONOLOGY 2019-2027 ($ MILLION)

    FIGURE 21   NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY GASTROINTESTINAL DISORDERS 2019-2027 ($ MILLION)

    FIGURE 22   NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY NEPHROLOGY 2019-2027 ($ MILLION)

    FIGURE 23   NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY OPHTHALMOLOGY 2019-2027 ($ MILLION)

    FIGURE 24   NORTH AMERICA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY OTHER APPLICATION 2019-2027 ($ MILLION)

    FIGURE 25   PORTER’S FIVE FORCE MODEL

    FIGURE 26   THE UNITED STATES ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)

    FIGURE 27   CANADA ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 2019-2027 ($ MILLION)

    1. GEOGRAPHICAL ANALYSIS
      • NORTH AMERICA
        • THE UNITED STATES
        • CANADA
    1. MARKET BY TYPES
      • GENERIC APIS
      • INNOVATIVE APIS
    2. MARKET BY MANUFACTURERS
      • CAPTIVE APIS
      • MERCHANT APIS
    3. MARKET BY SYNTHESIS
      • BIOTECH
        • MONOCLONAL ANTIBODIES
        • RECOMBINANT PROTEINS
        • VACCINES
      • SYNTHETIC
    4. MARKET BY APPLICATION
      • CARDIOVASCULAR DISEASE
      • ONCOLOGY
      • CNS AND NEUROLOGICAL DISORDERS
      • ORTHOPEDIC DISORDERS
      • ENDOCRINOLOGY
      • PULMONOLOGY
      • GASTROINTESTINAL DISORDERS
      • NEPHROLOGY
      • OPHTHALMOLOGY
      • OTHER APPLICATION

    To request a free sample copy of this report, please complete the form below :

    We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

      Choose License Type